26 patents
Utility
Glucagon-receptor selective polypeptides and methods of use thereof
12 Dec 23
This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof.
William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
Filed: 30 Nov 21
Utility
Methods comprising continuous administration of exenatide and co-administration of a drug
23 May 23
Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.
Andrew Young, Michelle Baron
Filed: 13 Oct 20
Utility
Long Acting Glucagon Like POLYPEPTIDE-1 (GLP-1) Receptor Agonists and Methods of Use
2 Mar 23
This invention relates to isolated polypeptides that are long acting analogs of human GLP-1.
William Blackwell, Ved P. Srivastava, Mark Paulik
Filed: 16 Dec 21
Utility
Glucagon-receptor Selective Polypeptides and Methods of Use Thereof
20 Oct 22
This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof.
William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
Filed: 30 Nov 21
Design
Implant placement guide
30 Aug 22
Jay S. Smith, Michael R. Cole, Amy K. Whitson
Filed: 23 Oct 18
Utility
Suspension formulation comprising an insulinotropic peptide
15 Feb 22
A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described.
Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
Filed: 14 Jun 19
Utility
Long Acting Peptide Tyrosine Tyrosine (Pyy) Analogs and Methods of Use
6 Jan 22
This invention relates to isolated polypeptides that are long acting analogs of human PYY.
William Blackwell, Ved P. Srivastava, James M. Way
Filed: 16 Apr 21
Utility
Glucagon-receptor selective polypeptides and methods of use thereof
4 Jan 22
This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof.
William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
Filed: 29 Oct 19
Design
Implant removal tool and assembly
12 Oct 21
Jay S. Smith, Matthew Weber, James M. Sellers, Michael R. Cole, Amy K. Whitson, Rehan Azeem
Filed: 13 Jul 18
Utility
Implant Placement and Removal Systems
7 Oct 21
Devices, methods, and systems are provided for placing an implant into a patient and removing it therefrom.
Jay S. Smith, Michael R. Cole, James M. Sellers, Scott D. Lautenbach, Amy K. Whitson, Matthew Weber
Filed: 14 Dec 20
Utility
Rapid Establishment And/or Termination of Substantial Steady-state Drug Delivery
5 Aug 21
The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery.
Thomas R. Alessi, Kenneth Luskey
Filed: 14 Dec 20
Utility
Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug
5 Aug 21
Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.
Andrew YOUNG, Michelle BARON
Filed: 13 Oct 20
Design
Implant removal tool
2 Mar 21
Jay S. Smith, Michael R. Cole
Filed: 24 Jul 19
Utility
Implant placement and removal systems
23 Feb 21
Devices, methods, and systems are provided for placing an implant into a patient and removing it therefrom.
Jay S. Smith, Michael R. Cole, James M. Sellers, Scott D. Lautenbach, Amy K. Whitson, Matthew Weber
Filed: 2 Jun 16
Utility
THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1c
23 Dec 20
The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery.
Thomas R. Alessi, Michelle Baron
Filed: 22 Jan 20
Utility
Rapid establishment and/or termination of substantial steady-state drug delivery
21 Dec 20
The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery.
Thomas R. Alessi, Kenneth Luskey
Filed: 5 Jul 18
Utility
THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1c
18 Nov 20
The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery.
Thomas R. Alessi, Michelle Baron
Filed: 3 Aug 20
Utility
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
16 Nov 20
Provided is a method for administering to a subject, via an implantable delivery device, a continuous subcutaneous dose of glucagon-like peptide-1 (GLP-1) analog, where the subject is orally co-administered a drug after implantation of the implantable delivery device and during continuous subcutaneous dosing of the GLP-1 analog.
Andrew Young, Michelle Baron
Filed: 2 Jan 18
Utility
Glucagon-receptor Selective Polypeptides and Methods of Use Thereof
23 Sep 20
This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof.
William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
Filed: 28 Oct 19
Utility
Apparatus and Methods for Administration of a Nauseogenic Compound from a Drug Delivery Device
17 Jun 20
Provided is a method for treating a subject, comprising contacting the subject with a drug delivery device comprising a nauseogenic compound, wherein the drug delivery device administers the nauseogenic compound to the subject, and the contacting occurs after an administration of the drug delivery device comprising the nauseogenic compound to a human patient population during a first clinical trial; and wherein less than 10% of the human patient population, to whom the drug delivery device comprising the nauseogenic compound was administered, reported having nausea and/or vomiting during the first clinical trial.
Andrew YOUNG
Filed: 7 Mar 18